Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
Background Immune checkpoint inhibitors (ICIs) demonstrated improved overall survival (OS) in heavily pretreated unselected patients with metastatic gastro-esophageal junction (mGOJ)/gastric cancer (GC). Attempts to select patients based on programmed death-ligand 1 (PD-L1) expression appear to be suboptimal. A strong rationale suggests a prognostic role for inflammatory biomarkers for ICI-treated patients with mGOJ/GC. Objective Our objective was to assess whether inflammatory markers are associated with survival in ICI-treated patients with mGOJ/GC. Methods Ten inflammatory markers were retrospectively analyzed at baseline in 57 patients with mGOJ/GC with unknown PD-L1 status treated with second-line ICIs and correlated with OS. Selected variables were then analyzed in a multivariate Cox-regression model and used to build a GIPI nomogram. Results Neutrophil/lymphocyte ratio (NLR) and C-reactive protein (CRP) as continuous variables and albumin categorized as less than versus greater than 30 g/dL were the most significant predictors of OS and were used to build the GIPI nomogram. Nomogram-based lowest, mid-low, mid-high, and highest risk quartiles were associated with median OS (mOS) of 14.9, 7.1, 5.6, and 2.1 months, respectively (hazard ratio [HR] of highest vs. lowest risk 4.94; p = 0.0002). By optimally dichotomizing CRP and NLR, patients with one or more of the risk factors NLR > 6, CRP > 15 mg/L, and albumin < 30 g/dL (n = 29) had an mOS of 3.9 versus 14.2 months for patients with no risk factor (n = 28) (HR 2.48; p = 0.0015). Conclusions GIPI, combining NLR, CRP, and albumin, is the first inflammatory index with a significant prognostic value in patients with mOGJ/GC receiving ICIs. GIPI merits validation in independent cohorts and prospective clinical trials..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Targeted oncology - 15(2020), 3 vom: 24. Mai, Seite 327-336 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Formica, Vincenzo [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© Springer Nature Switzerland AG 2020 |
|---|
| doi: |
10.1007/s11523-020-00723-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2047113032 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2047113032 | ||
| 003 | DE-627 | ||
| 005 | 20230504151836.0 | ||
| 007 | tu | ||
| 008 | 200820s2020 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11523-020-00723-z |2 doi | |
| 035 | |a (DE-627)OLC2047113032 | ||
| 035 | |a (DE-He213)s11523-020-00723-z-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Formica, Vincenzo |e verfasserin |0 (orcid)0000-0002-5380-3144 |4 aut | |
| 245 | 1 | 0 | |a Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Nature Switzerland AG 2020 | ||
| 520 | |a Background Immune checkpoint inhibitors (ICIs) demonstrated improved overall survival (OS) in heavily pretreated unselected patients with metastatic gastro-esophageal junction (mGOJ)/gastric cancer (GC). Attempts to select patients based on programmed death-ligand 1 (PD-L1) expression appear to be suboptimal. A strong rationale suggests a prognostic role for inflammatory biomarkers for ICI-treated patients with mGOJ/GC. Objective Our objective was to assess whether inflammatory markers are associated with survival in ICI-treated patients with mGOJ/GC. Methods Ten inflammatory markers were retrospectively analyzed at baseline in 57 patients with mGOJ/GC with unknown PD-L1 status treated with second-line ICIs and correlated with OS. Selected variables were then analyzed in a multivariate Cox-regression model and used to build a GIPI nomogram. Results Neutrophil/lymphocyte ratio (NLR) and C-reactive protein (CRP) as continuous variables and albumin categorized as less than versus greater than 30 g/dL were the most significant predictors of OS and were used to build the GIPI nomogram. Nomogram-based lowest, mid-low, mid-high, and highest risk quartiles were associated with median OS (mOS) of 14.9, 7.1, 5.6, and 2.1 months, respectively (hazard ratio [HR] of highest vs. lowest risk 4.94; p = 0.0002). By optimally dichotomizing CRP and NLR, patients with one or more of the risk factors NLR > 6, CRP > 15 mg/L, and albumin < 30 g/dL (n = 29) had an mOS of 3.9 versus 14.2 months for patients with no risk factor (n = 28) (HR 2.48; p = 0.0015). Conclusions GIPI, combining NLR, CRP, and albumin, is the first inflammatory index with a significant prognostic value in patients with mOGJ/GC receiving ICIs. GIPI merits validation in independent cohorts and prospective clinical trials. | ||
| 700 | 1 | |a Morelli, Cristina |4 aut | |
| 700 | 1 | |a Patrikidou, Anna |4 aut | |
| 700 | 1 | |a Murias, Carmen |4 aut | |
| 700 | 1 | |a Butt, Sabeeh |4 aut | |
| 700 | 1 | |a Nardecchia, Antonella |4 aut | |
| 700 | 1 | |a Lucchetti, Jessica |4 aut | |
| 700 | 1 | |a Renzi, Nicola |4 aut | |
| 700 | 1 | |a Shiu, Kai-Keen |4 aut | |
| 700 | 1 | |a Roselli, Mario |4 aut | |
| 700 | 1 | |a Arkenau, Hendrik-Tobias |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Targeted oncology |d Springer International Publishing, 2006 |g 15(2020), 3 vom: 24. Mai, Seite 327-336 |w (DE-627)527561894 |w (DE-600)2274491-5 |x 1776-2596 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2020 |g number:3 |g day:24 |g month:05 |g pages:327-336 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11523-020-00723-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2020 |e 3 |b 24 |c 05 |h 327-336 | ||